Rui Kang Pharmaceutical Group Investments Limited provided earnings guidance for the nine months ended 30 September 2016. For the period, the company expected to increase significantly when compared with that of approximately HKD 24.4 million for the corresponding period in 2015. Such net loss of the Group was mainly due to a significant net loss of approximately HKD 22.8 million on financial assets at fair value through profit or loss (as opposed to a net gain of approximately HKD 0.3 million for the corresponding period in 2015); and the recognition of an impairment loss on trade receivables of approximately HKD 5.0 million during the 2016 third quarter period (as opposed to nil for the corresponding period in 2015) as certain trade debts had been long overdue and the recovery of which were considered as remote.